Novimmune’s Experimental Drug Selected for Oral Presentation at 2015 Annual Meeting of the American Society of Hematology (ASH)

Late-Breaking Abstract on NI-0501 for Treatment of Hemophagocytic Lymphohistiocytosis (HLH) One of Only Eight Accepted

GENEVA, 1 December 2015  — Novimmune, a Swiss biotech company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory and rare diseases, immune-related disorders and cancer, today announced that the abstract on Hemophagocytic Lymphohistiocytosis (HLH) will be presented in the Late-Breaking Abstracts oral session at the 2015 Annual Meeting of the American Society of Hematology in Orlando, Florida on Tuesday, December 8.

The late-breaking abstract reports the preliminary results from Novimmune’s pilot Phase 2 study in children with primary HLH treated with NI-0501, a fully human monoclonal antibody that targets interferon-gamma (IFNγ) and is the first treatment developed specifically for HLH. Novimmune’s abstract is one of only eight accepted and will be published in the ASH Annual Meeting’s Online Program and Abstracts as well as in Blood online.

“The development of a targeted treatment for HLH offers the possibility to tackle this devastating disease with an innovative therapeutic approach,” said Novimmune Chief Medical Officer Cristina de Min. “It also represents an opportunity to better understand the biology of the disease itself, providing hope for children suffering from HLH.”

“We remain committed to discovering and developing new medicines to provide treatment options for patients suffering from devastating diseases like HLH,” added Chief Executive Officer Jack Barbut.

Oral abstract presentation on HLH is as follows:

(1) Abstract Number: 87376

A Novel Targeted Approach to the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) with an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody (mAb), NI-0501: First Results from a Pilot Phase 2 Study in Children with Primary HLH


Authors: Michael Jordan, MD, Franco Locatelli, Prof, MD, PhD, Carl Allen, MD, PhD, Fabrizio De Benedetti, MD, PhD, Alexei A. Grom, MD, Maria Ballabio, MD, Walter Giovanni Ferlin, PhD, NI-0501-04 Study Group and Cristina De Min, MD

Session Information

Session Name: Late-Breaking Abstracts Session
Session Date: Tuesday, December 8, 2015
Session Time: 7:30 AM – 9:30 AM
Presentation Time: 8:00 AM
Room: Orange County Convention Center, Hall D
 

About Novimmune

Novimmune SA is a Swiss biopharmaceutical company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer. The company is headquartered in Geneva. More information is available on the company website at www.novimmune.com.